Abstract

Acute kidney injury (AKI) is associated with increased mortality in most critical settings. However, it is unclear whether its mild form (i.e. AKI stage 1) is associated with increased mortality also in non-critical settings. Here we conducted an international study in patients hospitalized with SARS-CoV-2 infection aiming 1. to estimate the incidence of AKI at each stage and its impact on mortality 2. to identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. We included 939 patients from medical departments in Moscow (Russia) and Padua (Italy). In-hospital AKI onset was identified in 140 (14.9%) patients, mainly with stage 1 (65%). Mortality was remarkably higher in patients with AKI compared to those without AKI (55 [39.3%] vs. 34 [4.3%], respectively). Such association remained significant after adjustment for other clinical conditions at admission (relative risk [RR] 5.6; CI 3.5- 8.8) or restricting to AKI stage 1 (RR 3.2; CI 1.8–5.5) or to subjects with AKI onset preceding deterioration of clinical conditions. After hospital admission, worsening of hypoxic damage, inflammation, hyperglycemia, and coagulopathy were identified as hospital-acquired risk factors predicting AKI onset. Following AKI onset, the AKI-associated worsening of respiratory function was identified as the main contributor to AKI-induced increase in mortality risk. In conclusion, AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk also at stage 1. The identification of hospital-acquired risk factors and exposures might help prevention of AKI onset and of its complications.

Highlights

  • Acute kidney injury (AKI) is associated with increased mortality in most critical settings

  • After adjustment for changes in PaO2/Fio[2] the association between AKI and mortality was no longer significant (RR 1.89; 95% C.I. 0.81–4.44) (Fig. 4). This international multi-center study conveys four key important messages: (1) AKI is a common complication of COVID-19 in patients hospitalized in non-intensive care units

  • (2) Beyond the established factors affecting AKI susceptibility, changes in inflammatory markers, glycemia, and indexes of coagulopathy and hypoxic damages represent hospital-acquired exposures increasing the risk of AKI. (3) AKI at any stage, including stage 1, is independently and strongly associated with mortality

Read more

Summary

Introduction

Acute kidney injury (AKI) is associated with increased mortality in most critical settings. To identify AKI risk factors at admission (susceptibility) and during hospitalization (exposures) and factors contributing to AKI-associated mortality. AKI is a common complication of Sars-CoV2 infection in non-intensive care settings where it markedly increases mortality risk at stage 1. Longitudinal studies evaluating exposures associated with the onset of AKI during hospitalization in COVID-19 patients as well as the impact of AKI at any stage on COVID-19 related mortality are scant. This multicenter international study aims at describing the incidence of AKI (any stage) in patients admitted to non-ICU medical departments (Padua, Italy, and Moscow, Russia) with COVID-19-associated pneumonia, and the relevant impact on mortality. We describe clinical and biochemical risk factors at admission (susceptibility) and hospital-acquired risk factors for AKI (exposures), and identify the conditions contributing to AKIassociated mortality in COVID-19 patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call